[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603798":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":34,"locations":43,"responsibleParty":57,"collaborators":34,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":34,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":34,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":80,"whyStopped":34,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: Dose A of ABBV-8736","EXPERIMENTAL","Participants will receive intravenous (IV) ABBV-8736 dose A every 2 weeks for a total of 3 doses.",[13],"Drug: ABBV-8736",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 1: Dose A of ABBV-8736 Placebo","PLACEBO_COMPARATOR","Participants will receive IV ABBV-8736 placebo dose A every 2 weeks for a total of 3 doses.",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Group 2: Dose B of ABBV-8736","Participants will receive IV ABBV-8736 dose B every 2 weeks for a total of 3 doses.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Group 2: Dose B of ABBV-8736 Placebo","Participants will receive IV ABBV-8736 placebo dose B every 2 weeks for a total of 3 doses.",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","ABBV-8736","Intravenous (IV) Infusion",[9,21],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Placebo","IV Infusion",[15,25],[40],{"name":41,"affiliation":5,"role":42},"ABBVIE INC.","STUDY_DIRECTOR",[44],{"facility":45,"status":34,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":34},"Acpru \u002FId# 277377","Grayslake","Illinois","60030","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-88.04175,42.34447,{"lat":55,"lon":54},{"type":58,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100603798","phase-1-a-study-to-evaluate-adverse-events-how-the-drug-is-tolerated-and-how-the-drug-moves-through-the-body-of-intravenous-infusions-of-abbv-8736-in-adult-healthy-volunteers-100603798",false,"NCT07141199","A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers","A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-8736 After Multiple Ascending Doses in Healthy Adult Subjects","Inclusion Criteria:\n\n* Body mass index (BMI) is \\>= 18.0 to \\\u003C= 32.0 kg\u002Fm\\^2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.\n\nExclusion Criteria:\n\n* History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.\n* History of any clinically significant sensitivity or allergy to any medication or food.\n* Prior exposure to a TREM1 agent.",true,"ALL","18 Years","55 Years",{"count":71,"type":72},24,"ACTUAL","INTERVENTIONAL",[75],"PHASE1","The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.",[78],"Healthy Volunteer",[78,31],"COMPLETED","2026-04-24",{"date":83,"type":72},"2026-04-28",{"date":85,"type":72},"2025-09-02",{"date":87,"type":72},"2026-03-23",{"name":5,"class":6},1]